Article Text

Download PDFPDF
Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C
  1. Aarthi Surendran1,
  2. Aditya Bhalla2 and
  3. Martin Brunel Whyte3
  1. 1Department of Diabetes and Endocrinology, Lewisham and Greenwich NHS Trust, University Hospital Lewisham, London, UK
  2. 2Department of Cardiology, Darent Valley Hospital, Dartford and Gravesham NHS Foundation Trust, Dartford, UK
  3. 3Department of Diabetes, King's College Hospital, London, UK
  1. Correspondence to Dr Aarthi Surendran; Aarthi.surendran{at}nhs.net

Abstract

There is a bidirectional relationship between hepatitis C and type 2 diabetes. The risk for developing type 2 diabetes is increased in patients with chronic hepatitis C virus (HCV) infection—with the prevalence of diabetes ranging from 13% to 33%. This is likely underpinned by insulin resistance. Type 2 diabetes may also be a predisposing factor for HCV infection. The new non-interferon-based therapeutic regimens for hepatitis C have transformed care and can eradicate disease. In this report, we show how such a regimen eradicated viral load, improved hepatocellular blood markers and significantly improved dysglycaemia, such that all glucose-lowering medication could be stopped.

  • Diabetes
  • Infection (gastroenterology)
  • Hepatitis C
  • Hepatitis and other GI infections

Statistics from Altmetric.com

Footnotes

  • Twitter @surendranaarthi, @mbwhyte1

  • Contributors AS has written the case report. AB has contributed to the areas outlining the case presentation and the image. MBW is the senior author and was the primary consultant who looked after the patient. He also has critically reviewed the report and made changes.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.